Screener
Amneal Pharmaceuticals, Inc. AMRX Specialty — Currency translation
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GoodwillForeignCurrencyTranslationGainLoss.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
| Line item | Affordable Medicines | Specialty | Av KARE | Total |
|---|---|---|---|---|
| Balance as of December 31, 2024 | $161,659 | $366,312 | $69,465 | $597,436 |
| Currency translation | (1,966) | — | — | (1,966) |
| Balance as of December 31, 2025 | 159,693 | 366,312 | 69,465 | 595,470 |
| Currency translation | (1,971) | — | — | (1,971) |
| Balance as of June 30, 2026 | $157,722 | $366,312 | $69,465 | $593,499 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s specialty — currency translation?
- Amneal Pharmaceuticals, Inc. (AMRX) reported specialty — currency translation of $0 in Q2 2026.
- What does specialty — currency translation mean?
- Captures the net gains or losses resulting from the conversion of financial statements of foreign subsidiaries within the specialty segment into the reporting currency. Fluctuations in this metric indicate exposure to foreign exchange volatility and the impact of global currency movements on segment performance.
Ask your AI about Amneal Pharmaceuticals, Inc.'s specialty — currency translation.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude